Format
Sort by

Send to

Choose Destination

Search results

Items: 3

1.

Results from HARMONY: an open-label, multicentre, 2-arm, phase 1b, dose-finding study assessing the safety and efficacy of the oral combination of ruxolitinib and buparlisib in patients with myelofibrosis.

Durrant ST, Nagler A, Guglielmelli P, Lavie D, le Coutre P, Gisslinger H, Chuah C, Maffioli M, Bharathy S, Dong T, Wroclawska M, Martinez-Lopez J.

Haematologica. 2019 May 9. pii: haematol.2018.209965. doi: 10.3324/haematol.2018.209965. [Epub ahead of print]

2.

EXPAND, a dose-finding study of ruxolitinib in patients with myelofibrosis and low platelet counts: 48-week follow-up analysis.

Vannucchi AM, Te Boekhorst PAW, Harrison CN, He G, Caramella M, Niederwieser D, Boyer-Perrard F, Duan M, Francillard N, Molloy B, Wroclawska M, Gisslinger H.

Haematologica. 2019 May;104(5):947-954. doi: 10.3324/haematol.2018.204602. Epub 2018 Nov 15.

3.

[Preliminary evaluation of health behavior in obese students from a selected group of Warsaw adolescents].

Oblacińska A, Wojciechowska A, Wrocławska M.

Med Wieku Rozwoj. 1999 Apr-Jun;3(2):303-13. Polish.

PMID:
10910659

Supplemental Content

Loading ...
Support Center